
NSE: NGLFINE · Healthcare · Pharmaceuticals · Market cap ₹1,926 Cr
· Prev close ₹2,934.30 · Volume 10.70 K · 52W ₹1,271–3,602
Same session as: Analysts/Institutional Investor Meet/Con. Call Updates, filed 12 Nov 2026, 10:50 pm IST
Generated NGL Fine-Chem Limited said the audio recording of its Q2 & H1 FY27 earnings conference call, held on November 12, 2026 at 11:00 AM IST, has been uploaded to…
Shown when the day move is above 5%: the most material filing of this session and the one before.
If profit compounds at 10.0% (CAGR) and the stock ends at 25×, buying at ₹3,118 returns about 7.9% CAGR over 10 years.
| Growth assumption | Profit growth (CAGR) | Return, 10Y CAGR |
|---|---|---|
| Yours | 10.0% | 7.9% |
| Delivered FY22–26 | — | — |
| Net profit, last 4 quarters vs the 4 before | — | — |
| Half the delivered pace | — | — |
This is an exit-multiple calculation, not a discounted cash flow. Inputs: EPS for the 4 quarters Dec 2025 to Sep 2026 ₹103.31, price ₹3,118.10 (12 Nov close). Formula: return = (EPS × exit P/E ÷ price)^(1/10) × (1 + growth) − 1. Net profit growth is applied to EPS, so the share count is held constant. A profit fall of 100% or more has no rate and is left blank. Dividends ignored. Arithmetic, not a forecast.